The Library
Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial
Tools
Tools
Tools
(2018) Adjuvant bevacizumab for melanoma patients at high risk of recurrence : survival analysis of the AVAST-M trial. Annals of Oncology, 29 (8). pp. 1843-1852. doi:10.1093/annonc/mdy229
|
PDF
WRAP-Adjuvant-bevacizumab-melanoma-high-risk-Marshall-2018.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (366Kb) | Preview |
Official URL: https://doi.org/10.1093/annonc/mdy229
Abstract
Background
Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.
Patients and methods
Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers.
Results
Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18–88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82–1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74–0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78–1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21).
Conclusions
Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab.
| Item Type: | Journal Article | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) | |||||||||||||||
| Divisions: | Faculty of Medicine > Warwick Medical School | |||||||||||||||
| SWORD Depositor: | Library Publications Router | |||||||||||||||
| Library of Congress Subject Headings (LCSH): | Bevacizumab, Melanoma, Cancer -- Patients -- Treatment | |||||||||||||||
| Journal or Publication Title: | Annals of Oncology | |||||||||||||||
| Publisher: | Oxford University Press | |||||||||||||||
| ISSN: | 0923-7534 | |||||||||||||||
| Official Date: | 1 August 2018 | |||||||||||||||
| Dates: |
|
|||||||||||||||
| Volume: | 29 | |||||||||||||||
| Number: | 8 | |||||||||||||||
| Page Range: | pp. 1843-1852 | |||||||||||||||
| DOI: | 10.1093/annonc/mdy229 | |||||||||||||||
| Status: | Peer Reviewed | |||||||||||||||
| Publication Status: | Published | |||||||||||||||
| Access rights to Published version: | Open Access | |||||||||||||||
| RIOXX Funder/Project Grant: |
|
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
